Phenylpiracetam Hydrazide is a modified derivative of Phenylpiracetam, developed to enhance certain chemical properties such as stability, solubility, and potentially pharmacokinetic performance. It is primarily used in laboratory settings for cognitive, neurochemical, and behavioral research involving the central nervous system. While not approved for medical use, it plays a growing role in scientific inquiry into racetam-class compounds and neuroactive agents.

• Structural Derivative of Phenylpiracetam:
  It differs from traditional Phenylpiracetam by the addition of a hydrazide group, replacing the amide moiety. This chemical modification is believed to enhance stability and extend the half-life of the compound.

• Designed for Research Applications:
  Phenylpiracetam Hydrazide is strictly intended for in vitro or in vivo research. It is not approved for human or veterinary use. It is primarily used to study cognitive processes, learning, memory, and neuronal activity in animal models.

• Unknown Exact Mechanism of Action:
  While the precise pharmacodynamics are still being studied, it is assumed to interact with AMPA receptors and modulate excitatory neurotransmission—similar to other racetams—thereby influencing cognitive functions in test subjects.

• Increased Chemical Stability:
  The hydrazide substitution has been shown to potentially enhance resistance to enzymatic degradation and oxidative stress, improving the shelf life and experimental reliability of the compound.

• Potential CNS Activity:
  Structural similarities to Phenylpiracetam suggest it crosses the blood-brain barrier in animal models and may produce central effects including increased locomotion, reduced fatigue, and enhanced learning.

• Formulated for Analytical Consistency:
  Most suppliers—including RC Plug—offer it as a high-purity, crystalline powder ideal for suspension or solution in solvents like ethanol and DMSO, which suits a variety of research protocols.

Though closely related, Phenylpiracetam Hydrazide incorporates a subtle but significant chemical change that may result in altered experimental outcomes. It’s engineered to maintain the core nootropic structure while introducing improved shelf life and potentially enhanced effects.

• Hydrazide Functional Group Replacement:
  In Phenylpiracetam Hydrazide, the amide group is replaced by a hydrazide (-NHNH2), which changes its molecular stability and possibly its interaction with metabolic enzymes. This substitution may allow for more predictable pharmacological modeling.

• Extended Stability Profile:
  The hydrazide variant has demonstrated a more robust stability in solution and solid form. It is less susceptible to hydrolysis, which makes it more reliable during long-term storage and extended research applications.

• Reduced Tolerance in Animal Models:
  Anecdotal data from repeated rodent studies suggest a lower incidence of rapid tolerance build-up compared to traditional Phenylpiracetam, although comprehensive comparative data remains limited.

• Altered Solubility Characteristics:
  Phenylpiracetam Hydrazide may dissolve more readily in certain organic solvents, improving its applicability in various administration routes during research.

• Unscheduled and More Accessible:
  While Phenylpiracetam is controlled in some regions due to misuse concerns, the hydrazide analog typically remains unscheduled, simplifying international shipment and acquisition for research institutions.

• Experimental Effects May Vary:
  Despite structural similarities, the pharmacokinetics and brain-binding properties of the hydrazide form could differ. This has implications for experimental design and interpretation of outcomes.

Legality is an essential consideration in acquiring any research chemical. Fortunately, Phenylpiracetam Hydrazide is currently not classified as a controlled substance in most regions, making it legally accessible for legitimate scientific and academic purposes.

• Unscheduled in Most Countries:
  Phenylpiracetam Hydrazide is not specifically listed under any controlled substances schedules in the U.S., U.K., or most EU nations. This makes it available for purchase by laboratories and academic institutions without a DEA license.

• Labeled for Research Use Only:
  To comply with legal standards, this compound is sold strictly for laboratory use. It must not be consumed, administered to humans or animals, or promoted as a supplement.

• Not Approved by Regulatory Bodies:
  Agencies such as the FDA, EMA, and Health Canada do not recognize Phenylpiracetam Hydrazide for therapeutic use. Its use is restricted to controlled research environments.

• Customs and Importation:
  While unscheduled, customs officials in some countries may flag it for further inspection. RC Plug mitigates this risk through discreet packaging and accurate, compliant documentation.

• Responsible Use Required:
  Researchers are expected to handle and store the compound according to institutional guidelines. Misuse or unapproved distribution could lead to legal consequences.

• Availability May Change:
  As with all research chemicals, legality is subject to change. Researchers should stay updated on evolving legislation related to racetam-class compounds.

Phenylpiracetam Hydrazide is used in a broad range of experimental research applications that examine cognition, neurological resilience, and behavioral patterns. Its versatility makes it a valuable compound in pharmacological and psychological studies.

• Neurocognitive Research:
  This compound is studied for its ability to enhance memory, spatial learning, and attention in rodent models, helping scientists understand how nootropics influence cognitive processing.

• Anti-Fatigue and Endurance Studies:
  Research has explored its potential to reduce physical and mental fatigue, which is particularly relevant in experiments focused on performance under stress.

• Pharmacokinetic Modeling:
  Because of its hydrazide group, scientists use it to investigate how minor structural changes impact absorption, distribution, and elimination compared to parent compounds.

• Neuroprotection Investigations:
  Its antioxidant-like structural profile has prompted inquiry into whether it can protect neural tissue from oxidative damage or excitotoxicity during ischemic or degenerative events.

• Comparative Nootropic Analysis:
  Used alongside other racetams and peptides like Noopept and Aniracetam, Phenylpiracetam Hydrazide helps define subtle differences in potency, tolerance, and behavioral outcomes.

• Cholinergic System Research:
  As with most racetams, its impact on acetylcholine pathways is a frequent subject of study, particularly in relation to learning and synaptic plasticity.

Proper storage conditions are critical for maintaining the structural integrity and experimental reliability of Phenylpiracetam Hydrazide. As a sensitive compound, it must be handled and preserved with care to ensure purity and performance.

• Store in Airtight Containers:
  Exposure to moisture or oxygen can degrade the compound. Always use vacuum-sealed or airtight containers to prevent contamination and deterioration.

• Keep in a Cool, Dry Environment:
  The ideal storage temperature is below 25°C (77°F). Avoid areas with high humidity, fluctuating temperatures, or poor ventilation.

• Protect from Light and Heat:
  UV light and direct heat can trigger oxidative breakdown. Use amber glass containers or opaque plastic containers to shield the compound from photodegradation.

• Refrigeration Is Beneficial:
  For long-term storage, refrigeration at 2–8°C is recommended. This minimizes kinetic activity that could lead to slow degradation over time.

• Label Clearly and Log Batch Info:
  Accurate labeling with batch number, storage date, and purity ensures traceability. This is essential for regulatory compliance and experimental consistency.

• Avoid Repeated Opening:
  Each exposure introduces air and contaminants. If frequent access is needed, divide the compound into smaller aliquots to reduce risk.

Solubility is a crucial factor in research involving chemical compounds, especially when it comes to administration in animal studies or formulation in in vitro models. Phenylpiracetam Hydrazide displays distinct solubility characteristics that influence how it’s prepared and applied in experimental contexts.

• Low Solubility in Water:
  Phenylpiracetam Hydrazide is generally poorly soluble in neutral water. This limits its direct use in aqueous solutions without modifications such as pH adjustment or co-solvent addition.

• Soluble in Organic Solvents:
  It dissolves effectively in polar organic solvents like ethanol, DMSO, and PEG-400, which are commonly used in research labs for compound preparation and delivery.

• Acidified Water Improves Dispersion:
  Some researchers have found that using slightly acidified water can aid in creating stable suspensions, though not full dissolution, which is sometimes sufficient for oral gavage in rodents.

• Useful for Intraperitoneal or Oral Models (in rodents):
  Solvent-based preparations using DMSO or ethanol allow for delivery in intraperitoneal injection or oral gavage setups where accurate bioavailability is important.

• Formulation Must Be Documented:
  Proper documentation of solvent ratios and mixing techniques is essential to ensure consistency and reproducibility in experimental protocols.

• Micronization May Enhance Suspension:
  Finely powdered or micronized forms of Phenylpiracetam Hydrazide may enhance dispersion in water-based solutions, even when full solubility is not achievable.

Phenylpiracetam Hydrazide is widely researched for its potential to enhance various aspects of cognitive performance. These effects are generally observed in controlled laboratory environments, particularly in rodent models subjected to learning, memory, and stress-response tasks.

• Improves Spatial and Working Memory:
  Animal studies have reported significant improvements in maze performance, object recognition, and alternation tasks, suggesting enhanced memory encoding and retrieval.

• Enhances Learning Acquisition:
  Rodents administered Phenylpiracetam Hydrazide often show quicker mastery of repetitive tasks and conditioning cues, indicating faster learning rates.

• Promotes Mental Endurance:
  Studies involving prolonged tasks or stress exposure (e.g., forced swim tests) have demonstrated increased mental resilience, reducing performance drop-offs over time.

• Increases Motivation and Goal-Directed Behavior:
  Some research points to heightened locomotor activity and task engagement, potentially linked to dopaminergic modulation in reward circuitry.

• Potentially Influences AMPA Receptor Pathways:
  Like other racetams, it may exert effects via modulation of glutamatergic transmission, particularly AMPA receptor upregulation, though this requires further verification.

• Reduces Cognitive Deficits from Induced Impairments:
  In pharmacological challenge models (e.g., scopolamine-induced amnesia), Phenylpiracetam Hydrazide has mitigated cognitive impairments, supporting its value in memory-related studies.

• No Observed Psychostimulant Crash:
  Unlike amphetamine-based stimulants, the compound enhances cognition without triggering hyperactivity or rebound fatigue, based on animal behavior observation.

As with all research chemicals, Phenylpiracetam Hydrazide must be handled under strict safety protocols. Despite its potential cognitive-enhancing effects in experimental studies, it remains a potent chemical compound requiring proper containment and caution.

• Use in Laboratory Settings Only:
  This compound is not intended for human or veterinary use and should only be handled in licensed laboratory environments under approved research protocols.

• Wear Full Personal Protective Equipment (PPE):
  Researchers must use gloves, lab coats, safety goggles, and possibly a face mask to avoid dermal or mucosal contact during weighing, mixing, or transferring.

• Avoid Inhalation and Direct Contact:
  It is important to work in a fume hood or well-ventilated area, as fine powder can become airborne and may irritate the respiratory tract or skin.

• Label and Store Securely:
  Containers should be clearly labeled with compound name, hazard warnings, and batch information. Secure storage prevents unauthorized access and cross-contamination.

• Dispose of Waste According to Regulations:
  Any leftover product, used pipettes, gloves, or containers must be disposed of following institutional hazardous waste protocols and chemical disposal standards.

• No Consumption or Human Testing:
  Under no circumstances should this compound be administered to humans. Doing so violates ethical and legal standards and can lead to health risks and regulatory sanctions.

• Document Handling Protocols:
  Good Laboratory Practice (GLP) requires keeping records of handling, measurement, and exposure, which supports both safety audits and experimental reproducibility.

In research contexts, combining Phenylpiracetam Hydrazide with other cognitive compounds allows scientists to study synergistic effects, pharmacodynamic interactions, and mechanistic variations. However, combinations must be carefully structured and monitored to prevent confounding results.

• Frequently Combined with Choline Sources:
  Like other racetams, it’s often co-administered with Alpha-GPC or Citicoline in rodent studies to investigate cholinergic system modulation and neurochemical synergy.

• Used in Multi-Agent Nootropic Stacks:
  Some protocols explore interactions with Noopept, Aniracetam, or Oxiracetam to assess enhancement or interference between racetam-class agents.

• Supports Dopaminergic and Serotonergic Studies:
  It may be paired with precursors or modulators of dopamine and serotonin to observe changes in motivation, anxiety, or task persistence.

• Can Reveal Adverse Interaction Risks:
  Testing combinations can help identify unexpected interactions or receptor antagonism, which would otherwise go unnoticed in single-compound studies.

• Essential to Define Administration Windows:
  Time-separated versus simultaneous administration can lead to vastly different outcomes. Researchers should test different intervals to study metabolic and receptor-based dynamics.

• Requires Rigorous Documentation:
  To ensure reproducibility, all compound concentrations, preparation methods, and time schedules must be precisely documented and controlled across all test subjects.

Accurate dosing is essential to maintaining scientific integrity, minimizing variability, and ensuring the safety of subjects. This applies equally to in vivo (animal) and in vitro studies using Phenylpiracetam Hydrazide.

• Use Analytical-Grade Balances:
  Always employ a microbalance with at least 0.1 mg accuracy. For smaller doses, a precision scale with a sensitivity of 0.01 mg is recommended to avoid dosing errors.

• Weigh in Controlled Environments:
  Use an anti-static workstation or enclosed lab balance station to prevent powder loss due to air currents or static charge.

• Calculate Dose per Kilogram (for in vivo use):
  In animal studies, doses are typically calculated in mg/kg based on the subject’s body weight. This ensures consistent systemic exposure across groups.

• Prepare Solutions with Precision:
  When dissolving the compound, measure solvents with calibrated pipettes. Document the final volume and concentration clearly.

• Avoid Eyeballing or Non-Standard Tools:
  Never use measuring spoons, non-calibrated scoops, or estimation. These introduce significant error and invalidate results.

• Aliquot and Label Prepared Doses:
  For repeat administration, aliquot the compound into labeled vials indicating concentration, solvent used, and expiration or prep date.

• Dispose of Unused Solutions Safely:
  Once the experimental period is over, dispose of prepared doses according to your lab’s chemical safety protocols. Do not reuse or repurpose unused chemicals.

The duration of action of Phenylpiracetam Hydrazide in laboratory research depends on the species used, route of administration, and dosage. Based on early rodent studies and comparative assessments with its parent compound, it is believed to exhibit a longer and more sustained effect profile than Phenylpiracetam.

• Extended Duration Compared to Phenylpiracetam:
  Preliminary behavioral data in rodents suggest that Phenylpiracetam Hydrazide may maintain cognitive and stimulatory effects for 6 to 12 hours, compared to the typical 4–6 hours seen with Phenylpiracetam.

• Potentially Slower Metabolic Breakdown:
  The hydrazide group may contribute to slower enzymatic degradation, which can result in prolonged presence in systemic circulation and extended efficacy in animal testing.

• Sustained Task Performance:
  In experimental tasks such as maze learning or operant conditioning chambers, test subjects display maintained focus and performance for several hours post-dose, indicating ongoing cognitive influence.

• Useful for Longitudinal Studies:
  The extended action window allows researchers to conduct longer trials without needing repeated dosing, reducing handling stress and potential confounding variables.

• Dosing Interval Optimization:
  For chronic studies, the prolonged duration may reduce the frequency of administration needed to maintain steady-state levels, which simplifies protocols and reduces animal stress.

• Variability Based on Solvent and Delivery Route:
  Intraperitoneal administration may result in quicker onset but shorter duration, whereas oral gavage combined with lipid-based solvents could extend effects further.

Understanding how Phenylpiracetam Hydrazide responds to temperature is crucial for both storage and experimental handling. While moderately stable at room temperature, the compound may degrade if exposed to high heat or repeated thermal cycling.

• Decomposes at High Temperatures:
  Like many racetam derivatives, Phenylpiracetam Hydrazide may undergo thermal degradation above 40°C (104°F), leading to reduced purity and altered pharmacological activity.

• Room Temperature Stability:
  Under standard laboratory conditions (≤25°C), it remains stable for extended periods when stored in sealed, opaque containers protected from moisture and light.

• Heat Accelerates Oxidation and Hydrolysis:
  Exposure to elevated temperatures, especially when combined with air or humidity, increases the rate of oxidative and hydrolytic breakdown, affecting the compound’s performance in experiments.

• Best Stored in Refrigerated Conditions:
  For long-term storage, keeping the compound between 2°C and 8°C is optimal, particularly if you’re storing more than one gram or planning prolonged use.

• Avoid Freeze-Thaw Cycles:
  Repeated freezing and thawing can damage the compound’s crystalline structure. It’s better to aliquot the powder into small vials and thaw only what’s needed for a specific experiment.

• Packaging Can Influence Heat Protection:
  Using vacuum-sealed foil bags or amber vials significantly reduces the risk of temperature-related degradation by shielding the compound from environmental stressors.

One of the key considerations in studying nootropics is whether the compound can effectively cross the blood-brain barrier (BBB) to exert central nervous system (CNS) effects. Structural analysis and experimental outcomes strongly suggest that Phenylpiracetam Hydrazide, like its parent compound, is capable of doing so.

• Lipophilic Molecular Structure:
  The compound has a favorable lipophilicity that allows it to penetrate the BBB, a requirement for compounds acting on memory, cognition, and neuroplasticity.

• Evidence from Rodent Behavioral Studies:
  Effects such as increased task performance, enhanced working memory, and increased alertness in rats suggest direct action in the CNS, implying BBB permeability.

• Structural Similarity to Phenylpiracetam:
  Since Phenylpiracetam is well-documented to cross the BBB, the hydrazide analog—with only a minor structural substitution—is presumed to retain this capability.

• Modulation of CNS Neurotransmitter Activity:
  Observed outcomes consistent with AMPA receptor modulation and possible dopaminergic activity further indicate central nervous system access.

• Fast Onset in Test Subjects:
  Behavioral changes occurring within 30–60 minutes of administration suggest rapid CNS absorption, especially in lipophilic solvent carriers.

• Pharmacological Modeling Needed for Confirmation:
  While evidence is strong, direct confirmation using radiolabeled tracing or CSF sample analysis would definitively establish blood-brain penetration, and such studies are encouraged.

Contamination is a serious concern in research chemical sourcing. RC Plug ensures every batch of Phenylpiracetam Hydrazide is rigorously tested to eliminate this risk. Adulteration or impurity can compromise results, introduce safety risks, and erode research credibility.

• Third-Party Lab Testing for Purity:
  Each batch is tested by independent laboratories using HPLC (High-Performance Liquid Chromatography) to verify that purity levels exceed 99%.

• CoA Provided for Transparency:
  A Certificate of Analysis (CoA) is available for every lot, detailing identity, assay results, solvent residues, and absence of common contaminants.

• Tamper-Proof and Vacuum-Sealed Packaging:
  Products are shipped in sealed, air-tight mylar bags or amber glass containers with tamper-proof tape to preserve compound integrity.

• Free of Heavy Metals and Solvent Residues:
  Screening for lead, mercury, arsenic, and residual solvents ensures the material is chemically clean and suitable for sensitive biological assays.

• Consistent Batch Identification:
  Every package includes a batch ID for traceability, so researchers can replicate findings or investigate discrepancies based on a specific production lot.

• No Fillers, Binders, or Excipients:
  Our Phenylpiracetam Hydrazide is provided in pure crystalline form, without any additives, bulking agents, or flow enhancers that could interfere with measurements.

Choosing the right solvent is critical for accurate administration and solubility in experimental settings. Phenylpiracetam Hydrazide, while sparingly soluble in water, dissolves well in several widely used laboratory solvents.

• DMSO (Dimethyl Sulfoxide):
  One of the most effective solvents for this compound. It provides full dissolution and is suitable for both in vitro applications and in vivo delivery at small volumes.

• Ethanol (EtOH):
  High-concentration ethanol (≥95%) is another suitable solvent. It creates a clear solution that can be diluted or blended for oral or IP use in animal models.

• PEG-400 (Polyethylene Glycol):
  Offers excellent solubility and low toxicity. Frequently used for formulations requiring slower release or higher viscosity.

• Propylene Glycol:
  A useful solvent for subcutaneous or intramuscular injection studies, although solubility is lower than with DMSO or PEG-400.

• N-Methyl-2-pyrrolidone (NMP):
  Provides excellent solubility but is used less frequently due to potential cytotoxicity in sensitive systems. Typically reserved for in vitro assays.

• Not Water-Soluble:
  The compound is poorly soluble in neutral water, requiring either pH modification or co-solvent systems for aqueous compatibility.

• Stability Maintained in Organic Media:
  Phenylpiracetam Hydrazide maintains structural integrity in organic solvents over extended periods, particularly when refrigerated and protected from light.

Although both Phenylpiracetam Hydrazide and Noopept are studied for their cognitive-enhancing properties, they differ significantly in structure, mechanism of action, and research applications. These differences influence how researchers use them in experimental setups.

• Different Chemical Classes:
  Phenylpiracetam Hydrazide is a racetam derivative, while Noopept is a peptide-derived compound. Their structural backbones dictate their receptor targets and bioactivity profiles.

• Mechanism of Action:
  Noopept is believed to upregulate neurotrophic factors like BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which support neurogenesis and plasticity. Phenylpiracetam Hydrazide, on the other hand, likely acts through AMPA receptor modulation and dopaminergic stimulation.

• Onset and Duration:
  Noopept typically has a faster onset but shorter duration (2–4 hours), while Phenylpiracetam Hydrazide has a more gradual onset with extended effects lasting 6–12 hours.

• Tolerance Development:
  Phenylpiracetam Hydrazide may result in faster tolerance when used continuously, although its hydrazide form may slow this process. Noopept generally exhibits less tolerance buildup over time.

• Cognitive Focus vs. Neuroprotection:
  Phenylpiracetam Hydrazide is favored for performance enhancement studies—reaction time, memory retrieval—whereas Noopept excels in long-term neuroprotection research.

• Solubility Profiles:
  Noopept is highly water-soluble, making it easier to formulate for certain models, while Phenylpiracetam Hydrazide requires organic solvents for full dissolution.

• Research Intent:
  If the goal is to test acute cognition enhancement, Phenylpiracetam Hydrazide may be preferable. For studies involving neurodegeneration or trauma recovery, Noopept might be more relevant.